Phase 3 Lymphoma Trial, Completed

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with follicular lymphoma (a type of slow-growing blood cancer) confirmed by a tissue sample, at stage II or higher, and your cancer cells test positive for a marker called CD20, with a grade of 1, 2, or 3a.
• Your lymphoma is considered "low tumor burden," meaning your blood test results, swollen lymph nodes, and organ sizes fall within certain limits set by a medical guideline called the GELF criteria (confirm with trial site for your specific test results).
• You do not have symptoms such as persistent fever, heavy night sweats, or significant unexplained weight loss (more than 10% of your body weight in 6 months).
• You have no tumors larger than 7 cm, fewer than 3 swollen lymph nodes larger than 3 cm, and no dangerous fluid build-up around your lungs or abdomen.
• Your blood counts (platelets, red blood cells, and white blood cells) are within acceptable ranges.
• You have never previously been treated for your follicular lymphoma, except possibly localized radiation therapy for an earlier limited-stage diagnosis.

Who may not be able to join:

• You have previously received chemotherapy, rituximab, or any other monoclonal antibody treatment.
• You had radiation therapy fewer than 28 days before joining the study.
• You will need to take other experimental drugs, chemotherapy, hormone-based cancer treatment, radiation, or immunotherapy at the same time as this trial.
• You currently need ongoing treatment with high-dose steroid medications (equivalent to more than 20 mg per day of prednisolone).
• Your lymphoma has changed into a faster-growing, higher-grade type.
• You have had another cancer within the past 5 years, with some exceptions such as certain treated skin cancers, cervical cancer in situ, breast cancer in situ, or a very early-stage prostate cancer — provided you were fully treated and have had no recurrence (confirm with trial site).
• Your body surface area is calculated to be greater than 3.0 m² (confirm with trial site).
• You have had major surgery (other than a lymph node biopsy) within 28 days before joining the study.
• You have a known immune system disorder, or you are HIV positive.
• You have a serious active infection, or a long-lasting infection that could get worse if your immune system is suppressed.
• You have tested positive for hepatitis B or hepatitis C.
• You currently have active tuberculosis (TB).
• Your lymphoma has spread to your brain, spinal cord, or the lining around them, or you have a history of lymphoma in the brain.
• You have had a severe allergic reaction to a biological medicine, or you are allergic to any component of the trial drug, including products derived from mice.
• You have significant heart problems, such as serious heart failure, unstable chest pain, or uncontrolled irregular heartbeat.
• You have uncontrolled high blood pressure or a history of stroke or other brain blood vessel disease.
• You have other serious medical or psychological conditions that the doctor feels would prevent you from safely participating.
• You have taken any other experimental or unapproved drug within 4 weeks (or longer, depending on the drug) before starting the trial.
• You have received a live or weakened vaccine within 6 weeks before your screening appointment.
• You are pregnant, breastfeeding, or planning to become pregnant during treatment or within 12 months after your last dose.
• You are a staff member at the trial site, a family member of such staff, or an employee of the company running the trial who is directly involved in its conduct.

Important: Always verify eligibility with the trial site directly before applying.